Compared to traditional antibodies,
nanobodies are significantly smaller in size, which is advantageous for penetrating
tumors and crossing the blood-brain barrier. The protruding CDR3 regions of
nanobodies make them better at targeting hidden epitopes, and their simple
structure makes them ideal for assembly into bispecific/multispecific antibodies
or CAR proteins for cell therapy. To overcome the difficulties of discovering
nanobodies from natural nanobody-producing species (e.g., camel, shark),
Biocytogen genetically engineered RenNano® mice to produce fully human heavy chain-only antibodies (HCAbs).
RenNano-derived HCAbs exhibit sequence diversity, optimal affinity, superb
hydrophilicity, suitable thermostability and favorable PK properties. In our
first webinar in the new year, Dr. Yi (Benny) Yang will outline the current landscape
of nanobody-based therapeutics, introduce the capability of the RenNano
platform with case study examples, and describe Biocytogen’s “Nano 100 Project”,
designed for large-scale nanobody discovery.